AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
HRR Prevalence in LatAm PROSPECT Study
Completed
- Conditions
- Castration-resistant Prostate Cancer
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 388
- Registration Number
- NCT04962880
- Locations
- 🇵🇪
Research Site, Lima, Peru
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
Phase 3
Active, not recruiting
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 712
- Registration Number
- NCT04960709
- Locations
- 🇻🇳
Research Site, Hue, Vietnam
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
Phase 1
Terminated
- Conditions
- Advanced Solid Tumours
- Interventions
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2022-09-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5
- Registration Number
- NCT04959266
- Locations
- 🇪🇸
Research Site, Malaga, Spain
A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT04958226
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
A Study to Assess the Pharmacokinetics (Uptake of Drugs by the Body), Safety and Tolerability of AZD4831 in Participants With Severe Renal Impairment and Healthy Volunteers
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2022-04-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT04949438
- Locations
- 🇧🇬
Research Site, Sofia, Bulgaria
A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3
- Registration Number
- NCT04949425
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy Participants
Phase 1
Completed
- Conditions
- Solid and Hematological Malignancies
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT04944771
- Locations
- 🇩🇪
Research Site, Berlin, Germany
MEOI and HRQoL in CLL Patients Treated With BTKis
Completed
- Conditions
- Chronic Lymphocytic Leukemia
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 23
- Registration Number
- NCT04938141
- Locations
- 🇺🇸
Research Site, York, Pennsylvania, United States
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
Phase 4
Completed
- Conditions
- Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 103
- Registration Number
- NCT04930536
- Locations
- 🇮🇳
Research Site, New Delhi, India
Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
Phase 3
Active, not recruiting
- Conditions
- Active Systemic Lupus Erythematosus
- Interventions
- Drug: placebo
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 277
- Registration Number
- NCT04931563
- Locations
- 🇹🇭
Research Site, Bangkok, Thailand
© Copyright 2025. All Rights Reserved by MedPath